Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis

Clinical and Molecular Hepatology(2025)10.3350/cmh.2025.0825Source: DataRank Database

Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis is a research paper published in Clinical and Molecular Hepatology (2025). On theSindex it has a DataRank of 0.104. It has been cited 1 time.

N/A

0.104DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (30)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.104

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (10)

Daniel Fulop ORCID,Vy H. Nguyen ORCID,Eric M. Przybyszewski ORCID,Jiunn Song ORCID,Allison J. Carroll ORCID

Live enrichment

PubMed:41215582 PMC:PMC12835736

National Institutes of Health

Grant: R01 CA255621

National Institutes of Health

Grant: U01 CA288375

Gilead Sciences

goldLicense: cc-by-nc

publisherhttps://doi.org/10.3350/cmh.2025.0825

publisherhttp://e-cmh.org/upload/pdf/cmh-2025-0825.pdf

publisherhttp://e-cmh.org/journal/view.php?doi=10.3350/cmh.2025.0825

repositoryhttps://doaj.org/article/4e420f8f634b4eb3aee2048b929233ed

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12835736/

Fields of Study

HumansDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsMaleDipeptidyl-Peptidase IV InhibitorsFemaleMiddle AgedLiver CirrhosisDisease ProgressionRetrospective StudiesAgedFatty LiverAdult

MeSH Terms

HumansFatty LiverLiver CirrhosisDiabetes Mellitus, Type 2Disease ProgressionRetrospective StudiesAdultAgedMiddle AgedFemaleMaleDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 Inhibitors

Keywords

Liver fibrosisFatty liverfibrosisMasld

Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis

FAIR Checklist

DataRank Breakdown

Authors (10)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)